NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $372,596 | -21.9% | 47,404 | -0.7% | 0.00% | – |
| Q2 2023 | $476,842 | +10.9% | 47,732 | -1.4% | 0.00% | – |
| Q1 2023 | $430,094 | +156.9% | 48,434 | +217.6% | 0.00% | – |
| Q4 2022 | $167,423 | -15.9% | 15,248 | -0.2% | 0.00% | – |
| Q3 2022 | $199,000 | +18.5% | 15,278 | +14.9% | 0.00% | – |
| Q2 2022 | $168,000 | -10.2% | 13,297 | -0.4% | 0.00% | – |
| Q1 2022 | $187,000 | -51.0% | 13,349 | +1.4% | 0.00% | – |
| Q4 2021 | $382,000 | -20.4% | 13,171 | -17.8% | 0.00% | – |
| Q3 2021 | $480,000 | +34.1% | 16,024 | +18.8% | 0.00% | – |
| Q2 2021 | $358,000 | – | 13,484 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |